IRIS
LAVATELLI, FRANCESCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.807
AS - Asia 2.674
EU - Europa 2.063
SA - Sud America 328
Continente sconosciuto - Info sul continente non disponibili 160
AF - Africa 148
OC - Oceania 6
Totale 9.186
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.717
CN - Cina 1.151
SG - Singapore 656
IE - Irlanda 550
HK - Hong Kong 289
RU - Federazione Russa 262
DE - Germania 241
FI - Finlandia 239
BR - Brasile 237
VN - Vietnam 234
IT - Italia 205
FR - Francia 125
UA - Ucraina 118
ZA - Sudafrica 105
GB - Regno Unito 97
IN - India 86
CA - Canada 45
SE - Svezia 42
JP - Giappone 40
BD - Bangladesh 37
ES - Italia 37
TR - Turchia 33
AR - Argentina 30
PL - Polonia 27
IQ - Iraq 26
MX - Messico 26
NL - Olanda 20
PK - Pakistan 18
MA - Marocco 17
VE - Venezuela 16
ID - Indonesia 14
AT - Austria 13
BE - Belgio 13
CO - Colombia 13
LT - Lituania 13
EC - Ecuador 12
SA - Arabia Saudita 12
AE - Emirati Arabi Uniti 8
CZ - Repubblica Ceca 8
IL - Israele 8
CL - Cile 6
KR - Corea 6
PT - Portogallo 6
UY - Uruguay 6
AL - Albania 5
AU - Australia 5
AZ - Azerbaigian 5
EG - Egitto 5
ET - Etiopia 5
GR - Grecia 5
HU - Ungheria 5
MY - Malesia 5
PE - Perù 5
UZ - Uzbekistan 5
IR - Iran 4
JM - Giamaica 4
JO - Giordania 4
PH - Filippine 4
SK - Slovacchia (Repubblica Slovacca) 4
TH - Thailandia 4
BO - Bolivia 3
CH - Svizzera 3
DK - Danimarca 3
DZ - Algeria 3
EE - Estonia 3
HN - Honduras 3
LB - Libano 3
LK - Sri Lanka 3
LV - Lettonia 3
RS - Serbia 3
TN - Tunisia 3
VG - Isole Vergini Britanniche 3
BG - Bulgaria 2
BH - Bahrain 2
CR - Costa Rica 2
EU - Europa 2
GA - Gabon 2
GE - Georgia 2
HR - Croazia 2
KG - Kirghizistan 2
MD - Moldavia 2
MN - Mongolia 2
NG - Nigeria 2
NI - Nicaragua 2
NP - Nepal 2
RO - Romania 2
TT - Trinidad e Tobago 2
AM - Armenia 1
BY - Bielorussia 1
CY - Cipro 1
DO - Repubblica Dominicana 1
GH - Ghana 1
IS - Islanda 1
KE - Kenya 1
KH - Cambogia 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
ME - Montenegro 1
MK - Macedonia 1
Totale 9.017
Salva come PNG Salva come JPEG
Città #
Dublin 550
Chandler 439
San Jose 415
Singapore 362
Ashburn 360
Dallas 311
Hong Kong 284
Beijing 275
Jacksonville 186
Nanjing 179
Boardman 167
Helsinki 122
Council Bluffs 105
Los Angeles 94
Johannesburg 89
Lauterbourg 84
Nanchang 84
Ho Chi Minh City 80
Princeton 80
Lawrence 77
Wilmington 72
Medford 71
New York 68
Hanoi 62
Munich 62
Shenyang 56
Hebei 55
Santa Clara 53
Moscow 46
Jiaxing 44
Changsha 42
Shanghai 41
Buffalo 40
Ann Arbor 38
Hangzhou 38
Pavia 36
Tokyo 34
Tianjin 33
Redondo Beach 31
São Paulo 30
Milan 29
Orem 28
Turku 23
Frankfurt am Main 21
Norwalk 21
Montreal 20
Warsaw 20
Piscataway 18
Woodbridge 18
Ankara 17
Chennai 16
Chicago 15
Denver 15
London 15
Poplar 15
The Dalles 15
Boston 14
Rio de Janeiro 14
San Francisco 14
Brussels 13
Phoenix 13
Atlanta 12
Avellino 12
Amsterdam 11
Brooklyn 11
Charlotte 11
Da Nang 11
Fairfield 11
Manchester 11
Seattle 11
Stockholm 11
Columbus 10
Falkenstein 10
Haiphong 10
Mexico City 10
Washington 10
Catania 8
Chandigarh 8
Toronto 8
Baghdad 7
Caracas 7
Dhaka 7
Houston 7
Rome 7
Verona 7
Belo Horizonte 6
Biên Hòa 6
Campina Grande 6
Cape Town 6
Curitiba 6
Hải Dương 6
Jinan 6
Lahore 6
Ningbo 6
Nuremberg 6
Pune 6
Redwood City 6
Vienna 6
Addis Ababa 5
Bologna 5
Totale 5.985
Salva come PNG Salva come JPEG
Nome #
Susceptibility to AA amyloidosis in rheumatic diseases: A critical overview. 220
A novel method for proteomic analysis of immunoglobulin light chains and attribution to a germline gene-based family 164
A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis 154
An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis 141
Functional correlates of N-terminal natriuretic peptide type B (NT-proBNP) response to therapy in cardiac light chain (AL) amyloidosis 138
A Strategy for Synthesis of Pathogenic Human Immunoglobulin Free Light Chains in E-coli 134
AMICA: an electronic patient record specifically designed for an amyloidosis network 134
Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure. 132
Amyloidogenic light chains induce human cardiac fibroblast toxicity through alteration of mitochondrial functionality 131
Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue. 128
Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays 128
Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients 125
Nutritional counseling improves quality of life and preserves body weight in systemic immunoglobulin light-chain (AL) amyloidosis 125
ATR-FTIR spectroscopy supported by multivariate analysis for the characterization of adipose tissue aspirates from patients affected by systemic amyloidosis 123
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 122
A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis 121
Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis 120
A practical approach to the diagnosis of systemic amyloidoses 118
Identification of Amyloidogenic Light Chains Requires the Combination of Serum-Free Light Chain Assay with Immunofixation of Serum and Urine 117
Patterns of relapse after upfront bortezomib therapy in AL amyloidosis 117
Prognostication of survival and progression to dialysis in AA amyloidosis 116
Biochemical markers in early diagnosis and management of systemic amyloidoses 115
Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide 114
Amyloid Formation by Globular Proteins: The Need to Narrow the Gap Between in Vitro and in Vivo Mechanisms 114
Single-molecule real-time sequencing of the M protein: Toward personalized medicine in monoclonal gammopathies 112
In situ characterization of protein aggregates in human tissues affected by light chain amyloidosis: a FTIR microspectroscopy study 112
Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib and thalidomide 111
Investigating heart-specific toxicity of amyloidogenic immunoglobulin light chains: A lesson from C. elegans 111
Dieta a contenuto controllato di proteine in pazienti affetti da amiloidosi AL con coinvolgimento renale 110
Correlation between serum concentrations of N-terminal natriuretic peptide type B (NT-proBNP) and troponin-I (TnI) in AL amyloidosis 110
A workflow management system for the biological samples exchange within the amyloidosis network 110
AL Amyloidosis Associated with IgM Monoclonal Protein: A Distinct Clinical Entity 109
The impact of renal function on the clinical performance of FLC measurement in AL amyloidosis 109
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 108
AMICA: an electronic patient record specifically designed for an amyloidosis network. 108
Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis 107
Proteotoxicity in cardiac amyloidosis: Amyloidogenic light chains affect the levels of intracellular proteins in human heart cells 107
Nutritional status independently affects quality of life of patients with systemic immunoglobulin light-chain (AL) amyloidosis 105
Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis 105
IceTrack: a biobank information management system maximizing flexibility and usability 104
Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response 103
Mass spectrometry characterization of light chain fragmentation sites in cardiac AL amyloidosis:insights into the timing of proteolysis 103
Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL amyloidosis 102
Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis 101
Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue 101
Amyloid fibrils containing fragmented ATTR may be the standard fibril composition in ATTR amyloidosis 98
A workflow management system for the biological samples exchange within the amyloidosis network 96
Changes in tissue proteome associated with ATTR amyloidosis: Insights into pathogenesis 95
Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome 95
Inherent Biophysical Properties Modulate the Toxicity of Soluble Amyloidogenic Light Chains 95
Malnutrition at Diagnosis Predicts Mortality in Patients With Systemic Immunoglobulin Light-Chain Amyloidosis Independently of Cardiac Stage and Response to Treatment. 94
Regulated expression of amyloidogenic immunoglobulin light chains in mice 92
Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy 92
A case of monoclonal gammopathy of renal significance 92
Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity. 91
Human wild-type and D76N β2-microglobulin variants are significant proteotoxic and metabolic stressors for transgenic C. elegans 90
Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient 89
Treatment of IgM-associated AL amyloidosis with the combination of rituximab, bortezomib and dexamethasone 86
The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). 84
Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: Prospective study in 206 patients 84
A mouse model of cardiac immunoglobulin light chain amyloidosis reveals insights into tissue accumulation and toxicity of amyloid fibrils 84
AA-amyloidosis in cats (Felis catus) housed in shelters 83
Degradation versus fibrillogenesis, two alternative pathways modulated by seeds and glycosaminoglycans 83
Concurrent structural and biophysical traits link with immunoglobulin light chains amyloid propensity 83
Clonal biomarkers for diagnosis and response to treatment assessment in light chain amyloidosis: The role of the laboratory 82
Dissecting the molecular features of systemic light chain (Al) amyloidosis: Contributions from proteomics 82
Modulating the cardiotoxic behaviour of immunoglobulin light chain dimers through point mutations 81
Age-related amyloidosis outside the brain: A state-of-the-art review 81
Truncation of the constant domain drives amyloid formation by immunoglobulin light chains 78
Novel mitochondrial protein interactors of immunoglobulin light chains causing heart amyloidosis 78
Protease-sensitive regions in amyloid light chains: what a common pattern of fragmentation across organs suggests about aggregation 78
Mass spectrometry-based proteomics as a diagnostic tool when immunoelectron microscopy fails in typing amyloid deposits 77
Novel mitochondrial protein interactors of immunoglobulin light chains causing heart amyloidosis 76
Cryo-EM structure of ex vivo fibrils associated with extreme AA amyloidosis prevalence in a cat shelter 76
Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach 76
Renal alterations in cats (Felis catus) housed in shelters and affected by systemic AA-amyloidosis: Clinicopathological data, histopathology, and ultrastructural features 75
Clinical proteomics for diagnosis and typing of systemic amyloidoses 73
The concurrency of several biophysical traits links immunoglobulin light chains with toxicity in AL amyloidosis 70
Shotgun protein profile of human adipose tissue and its changes in relation to systemic amyloidoses. 68
Clinical amyloid typing by proteomics: Performance evaluation and data sharing between two centres 68
Free light measurement identifies relapse and prompts to reconsider amyloid typing in a patient with AL amyloidosis 62
Proteomic characterization of amyloid deposits in transthyretin amyloidosis associated with various mutations 62
The workings of the amyloid diseases. 61
Zebrafish model of amyloid light chain cardiotoxicity: regeneration versus degeneration 61
Systemic amyloidoses and proteomics: The state of the art 59
Evaluation of response to treatment in a patient with light chain amyloidosis and low free light chain burden 56
Tissue biopsy for the diagnosis of amyloidosis: experience from some centres 56
Proteomics with Mass Spectrometry Imaging: Beyond Amyloid Typing 54
Proteomics in protein misfolding diseases. 51
A practical approach to the diagnosis of systemic amyloidoses 50
How do we improve treatments for patients with amyloidosis using proteomics? 48
Proteomics Fundamentally Advance the Diagnosis and Management of Amyloidosis 47
Perspectives in developments of mass spectrometry for improving diagnosis and monitoring of multiple myeloma and other plasma cell disorders 47
null 35
The Protein Network in Subcutaneous Fat Biopsies from Patients with AL Amyloidosis: More Than Diagnosis? 34
null 28
Renal amyloid‐A amyloidosis in cats: Characterization of proteinuria and biomarker discovery, and associations with kidney histology 24
Role of extracellular space and matrix remodeling in cardiac amyloidosis 21
null 6
Totale 9.186
Salva come PNG Salva come JPEG
Categoria #
all - tutte 40.716
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.716
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022306 0 5 2 4 6 2 6 39 20 3 38 181
2022/20231.410 181 116 18 82 120 121 10 59 623 8 32 40
2023/2024585 69 112 33 26 47 123 20 42 9 25 42 37
2024/20251.461 45 107 54 39 32 94 66 65 384 56 199 320
2025/20263.787 279 246 383 444 518 174 657 186 374 262 101 163
2026/2027196 77 119 0 0 0 0 0 0 0 0 0 0
Totale 9.186